Navigation Links
Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder
Date:1/26/2012

treated with tasimelteon for three months during a run-in phase.  Patients who respond to tasimelteon treatment during the run-in phase, as measured by the resetting and alignment of their body clock to the 24-hour day, will then be randomized either to receive placebo or to continue receiving tasimelteon for 2 months.  During the post-randomization phase, patients will be re-evaluated.  For more information, please visit http://clinicaltrials.gov/.

About Non-24-Hour Disorder

Non-24-Hour Disorder is a chronic circadian rhythm sleep disorder that affects more than 50 percent of the totally blind individuals in the U.S., or 65,000 to 95,000 people.  Non-24-Hour Disorder occurs almost entirely in individuals who are totally blind and lack the light sensitivity necessary to reset the circadian clock.  Without light perception, the brain's circadian rhythms, which guide many of the body's functions, including sleep, are not reset to a regular 24-hour cycle. 

Individuals with Non-24-Hour Disorder are unable to synchronize their internal clock to the 24-hour day-night cycle, which disrupts their sleep-wake cycle.  For more information, please visit http://24sleepwake.com/.

About Tasimelteon

Tasimelteon is the first compound in development for the treatment of Non-24-Hour Disorder.  Tasimelteon is a specific and potent agonist of the human MT1 and MT2 receptors.  Compounds that selectively bind to melatonin receptors are thought to be able to regulate the body clock, which may be useful to treat circadian rhythm disorders.  Tasimelteon is being studied in both Non-24 and Major Depressive Disorder (MDD). 

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of produc
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
2. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
5. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
6. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
7. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
8. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... MONMOUTH JUNCTION, N.J. , May 4, 2015 ... critical care immunotherapy company commercializing its CytoSorb® extracorporeal ... patients in multiple countries worldwide, will report Q1 ... Monday, May 11, 2015.  CytoSorbents, ... presentation webcast that will recount both operational and ...
(Date:5/4/2015)... , May 4, 2015 Dynatronics ... manufacturer and marketer of rehabilitation and physical therapy ... definitive agreements to raise approximately $4,000,000 in a ... and certain of its affiliates (together with its ... on the healthcare industry. The financing will provide ...
(Date:5/4/2015)... ROCKVILLE, Md. , May 4, 2015   ... of pathogen-specific therapeutics focused on protecting the microbiome, as ... Shallcross has been appointed Chief Financial Officer, Treasurer ... C. Evan Ballantyne who will be leaving the ... Mr. Shallcross brings to Synthetic Biologics operational, financial and ...
Breaking Medicine Technology:CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 4Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3
... , Inc., a full-service contract research organization (CRO), and ... combat the growing issue of antibiotic resistance, have partnered ... walk to benefit the Cystic Fibrosis (CF) Foundation through ... Aptalis Pharma) are also working together on clinical trials ...
... May 2, 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... March 31, 2012.  For the first quarter of 2012, the ... per share, compared with a net income of $2.9 million, ... 2011. This $3.8 million change in operating results is primarily ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6
(Date:5/3/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 03, 2015 ... . She has worked to enhance the well being of ... as a generalist in a hospital, followed by providing care for ... I worked with as an Adult Nurse Practitioner began wondering if ... coupled with the birth of my own children with my mentor ...
(Date:5/3/2015)... and LOS ANGELES, American Telemedicine Association 2015 Meeting ... vitaphone e-health solutions, a full-service telemedicine and ... of its new platform, VITA health services for ... VITA health services platform enables remote patient monitoring ... as congestive heart failure (CHF), diabetes, COPD, hypertension ...
(Date:5/3/2015)... 2015 " Bubbly Walrus ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... game. , The best games to play on smartphones are ... users killing brain cells with a video game that just ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 “ BolehVPN ” ... Report, which features the latest and coolest technology products available ... for NewsWatch, conducted the review and shared with viewers how ... everyone does these days is on computers and even more ... families and meet people all over the world. In terms ...
(Date:5/3/2015)... May 03, 2015 NuevaCare announced today ... two upcoming area seminars. The first event will take ... Regional Stroke Conference to be held at The Magnolia ... Wednesday, May 13 during the Dementia Conference to be ... “These seminars offer an excellent opportunity to learn about ...
Breaking Medicine News(10 mins):Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2
... agent selumetinib has shown promising results in people with ... led by cancer researchers at The Ohio State University. ... protein called MEK, which cancer cells need to proliferate ... lining the bile ducts and gall bladder. About 100,000 ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, ... that report the greatest number of satisfied inhabitants also ... Seemingly contradictory, the findings are probably explained by ... constantly compare oneself to others. "Deep down we ...
... will gather at Rice University,s Shepherd School of Music ... cognition and behavior and present the latest research findings ... a series of in-depth morning seminars, the scientific researchers ... the musicians learn concurrently about brain morphology, music perception ...
... MONDAY, April 25 (HealthDay News) -- New research suggests that ... regulating a brain wave known as the alpha rhythm, which ... small study, researchers found that those participants using meditation were ... told where to direct their attention -- after they finished ...
... association between computer and Internet use in adolescents and ... drunkenness and unprotected sex. "This research is based ... engaged in a behaviour is a way of learning ... candidate in School of Kinesiology and Health Studies. "Since ...
... examines the ion selectivity of cation-selective channels and transporters. ... the Journal of General Physiology ( www.jgp.org ... his introduction, a key tool in most recent studies ... which emphasize the fluid-like features of the selectivity filter ...
Cached Medicine News:Health News:Targeted agent selumetinib shows promise in biliary cancer 2Health News:'Happiest' States Show Highest Suicide Rates: Study 2Health News:'Happiest' States Show Highest Suicide Rates: Study 3Health News:Musicians and scientists to research mind and music at Rice University conference 2Health News:Meditation May Help Brain Block Out Distractions 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: